Birchview Capital, LP Immuno Gen, Inc. Transaction History

Birchview Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$3.75 - $20.05 $150,000 - $802,000	40,000 Added 26.67%	190,000 $3.59 Million
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $126,000 - $230,400	-40,000 Reduced 21.05%	150,000 $675,000
Q1 2020 May 12, 2020	BUY	$2.12 - $6.8 $21,200 - $68,000	10,000 Added 5.56%	190,000 $648,000
Q2 2019 Aug 06, 2019	BUY	$1.8 - $3.3 $162,000 - $297,000	90,000 Added 100.0%	180,000 $391,000
Q1 2019 May 03, 2019	BUY	$2.41 - $5.91 $163,880 - $401,880	68,000 Added 309.09%	90,000 $244,000
Q4 2018 Feb 06, 2019	BUY	$3.94 - $9.7 $86,680 - $213,399	22,000 New	22,000 $106,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Birchview Capital, LP with notifications on news.